Medscape has published the annual U.S. News and World Reports ranking of Rheumatology Hospitals, again honoring Johns Hopkins Hospital with the top spot, with runner up status going to the Cleveland Clinic, Hospital for Special Surgery, Mayo Clinic and Brigham and Women's Hospital.
Dr. John Cush RheumNow
5 years 2 months ago
CMAJ: nice full read review of biologic use during pregnancy.
1) autoimmune/arthritis pts may use biologics during pregnancy
2) mom/infant should avoid live vax 1st 6–12 mos
3) Minimal biologic transfer in breast milk
4) no risk of congenital anomalies
https://t.co/mlZTrDjXSi
Vanessa Ocampo - MD DrDDRheum
5 years 2 months ago
Top 10 things you should know about THE EYE in your rheumatology practice @CRASCRRheum
#uveitisclinic
#uveitisrheumatologyclinic
#kensingtoneyeinstitute https://t.co/SqRKOYa2N0
Dr. John Cush RheumNow
5 years 2 months ago
Another report of JAK inhibitor working in GVHD - Successful treatmente of joint & fascial involvement in GVHD with baricitinib. https://t.co/TQlPLCD2T7 https://t.co/474GpFKBo2
Dr. John Cush RheumNow
5 years 2 months ago
New ACR Rheumatoid Arthritis Guideline: Emphasis on Methotrexate
The ACR has issued new guidelines on the treatment of RA, addressing questions about initial treatment with methotrexate and minimizing reliance on glucocorticoids.
https://t.co/J9wmcZr17D https://t.co/Tf3G9sFgm9
Dr. John Cush RheumNow
5 years 2 months ago
Former Rheumatologist Settles Civil Fraud Claims for $2 Million for alleged False Claims Act violations. Charges were based on claims for improper medical treatments and false billing to a federal program. https://t.co/HZwrwDrkVk
Disease activity leads to poor outcomes; but does comorbidity add to this? A recent analysis suggests that while comorbidities do not affect long-term, functional outcomes, sociodemographic factors do affect outcomes in rheumatoid Arthritis (RA).
Sparks and colleagues have published data from the Global Rheumatology Alliance noting that among rheumatoid arthritis (RA) patients afflicted with COVID-19 infection, there was little influence of their baseline biologic or targeted synthetic (b/ts) disease-modifying antirheumatic drugs (DMARDs) COVID-19 outcomes (with the exception of rituximab and Janus kinase inhibitors).
Dr. John Cush RheumNow
5 years 2 months ago
ICYMI: Neuropsychiatric Events Common in Lupus
Neuropsychiatric (NP-SLE) or CNS lupus events range from mild to severe; several recent studies have noted that NPS lupus is common and should be screened for.
https://t.co/cBDZI8OLKD https://t.co/on4fA3P9GS
Dr. John Cush RheumNow
5 years 2 months ago
Fracture Risk with Low Dose Steroid
A large RA cohort analysis shows that low-dose glucocorticoid therapy in rheumatoid arthritis (RA) patients may carry an increased risk of vertebral osteoporotic (OP) fractures.
https://t.co/HcYpx8IDcB https://t.co/iVPjJHLNBX
Dr. John Cush RheumNow
5 years 2 months ago
Recent review of the epidemiology of rare Autoimmune Liver disease (PBC, PSC, AIH) shows prevalence (per 100 000) to( vary for PBC (1.91 to 40.2), for PSC (0.78 and 31.7) and for AIH (4.8 to 42.9/100,000) https://t.co/XbRYV5Qlwa
Dr. John Cush RheumNow
5 years 2 months ago
Dutch study of 644 t Early Psoriatic Arthritis pts shows that 17% had no psoriasis (PASI = 0), 71% had mild psoriasis (PASI < 7), 9% moderate psoriasis (7–12) and 4% had severe psoriasis (PASI > 12). PASI didnt fluctuate much in 1st year https://t.co/XW3QhJ65Oz
Janet Pope Janetbirdope
5 years 2 months ago
#ClinicalPearl Palmar erythema in #SLE #lupus is sometimes painful, may not be fixed and also may have erythema of distal fingers on flexor side https://t.co/C5mysB8pFS
Dr. John Cush RheumNow
5 years 2 months ago
ICYMI: Metanalysis of Tramadol efficacy & safety in knee or hip #OA. 6 RCTs (3,611 pts) showed little clinical benefit w/ 100/d or 200 mg/d; only 300mg/d was better vs PBO at pain & functional improvement. All doses had higher risk of GI, CNS AEs & W/D https://t.co/wDLHFQWFOe https://t.co/l4B83eUQrW
Dr. John Cush RheumNow
5 years 2 months ago
ICYMI: New-Onset IBD & IL-17 Inhibitors: What’s the Risk?
https://t.co/zXDQotDiWV
Patients w/ inflammatory/autoimmune diseases who initiated treatment w/ IL-17 inhibitors didnt have a higher risk for development of IBD, but only based on the severity of their underlying disease https://t.co/w3IpQkzmn7
